All articles tagged with #medicareadvantage
Humana beat Q2 estimates with adjusted EPS of $7.61 on revenue of $40.87 billion, driven by strength in insurance and CenterWell; the company maintained its 2026 adjusted EPS target of at least $9, with medical costs in line with expectations and a medical benefit ratio of 91.2%. Management expects 2027–2028 profitability improvements and more stable costs, though the stock fell about 6% after the report.
Top investors predict significant changes in healthcare by 2025, including increased court action over legislative changes, the sale of Illumina, and a resurgence in health tech mergers and IPOs. Dr. Oz is expected to lead CMS, making Medicare Advantage more accessible, while Apple is anticipated to revolutionize glucose monitoring with non-invasive technology. Health tech AI startups may struggle to sustain as standalone businesses, and cell therapy is predicted to regain prominence in treating solid tumors.
Cigna Group is in advanced discussions to sell its Medicare Advantage business to Health Care Service Corp in a deal potentially worth $3 billion to $4 billion. The sale would indicate a strategic shift for Cigna, which has seen the U.S. government reduce reimbursement rates for health insurers. Cigna's Medicare Advantage segment represents a small portion of its overall revenue, with the bulk coming from its commercial and pharmacy benefits divisions. The deal is expected to be announced soon unless negotiations falter.
Cigna is in the final stages of negotiations to sell its Medicare Advantage business to Health Care Service Corp. in a deal valued between $3 billion and $4 billion. This move represents a strategic shift for Cigna, which had previously been expanding in the Medicare sector. The sale comes after Cigna conducted an auction for the business, which generated approximately $7.9 billion in revenue in 2022 and had around 599,000 members as of the end of September.